Spinal Cord Injury Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Spinal Cord Injury Pipeline Insight 2023,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in the Spinal Cord Injury pipeline landscape. It covers the Spinal Cord Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spinal Cord Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Spinal Cord Injury Pipeline Report
- DelveInsight’s Spinal Cord Injury pipeline report depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Spinal Cord Injury treatment.
- The leading companies working in the Spinal Cord Injury Market include Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.
- Promising Spinal Cord Injury Pipeline Therapies in the various stages of development include KAI-1678, Tadalafil, NVG-291, GRNOPC1, MT-3921, ALMB-0166, NeuroAiD, and others.
- March 2023: Neuroplast announced a study of Phase 1 clinical trials of Neuro-Cells. Mono-center, open label study to investigate the safety of Neuro-Cells in 10 end stage (chronic) traumatic spinal cord injury (TSCI) patients, when administered once intrathecally. TSCI is a rare disease without cure perspectives and Neuro-Cells is an autologous fresh stem cells containing product (one batch / one patient). This phase I clinical study is an open clinical trial to investigate the safety of the intrathecal application of Neuro-Cells in the treatment of end stage (chronic), traumatic complete (AIS grade A) and incomplete (AIS grade B/C) SCI patients. To that purpose, after inclusion in this study >1 year and less than 5 years after their SCI-event, 10 patients will be included. All patients are invited to visit the trial hospital every month during this 3-months study for appreciation of their possible (S)AEs and/or SUSARs, for physical examination and a biochemical analysis of their blood/urine. Day 0 and day 90 they also undergo a comprehensive neurological examination, the AISIAms, ASIAss and Pain perception.
- August 2023: NervGen Pharma announced a study of Phase 1 & 2 clinical triails for NVG-291. A Single site (Shirley Ryan AbilityLab) Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects. To evaluate the effect of NVG-291 on descending connectivity in subjects with subacute and chronic SCI (20 subjects per Cohort and results will be analyzed separately) using objective electrophysiological measures, in addition to clinical assessments. To evaluate safety and tolerability of NVG-291 in a SCI population, as measured by clinical assessments (Physical Examination, Vital Signs, ECG, etc.) as well as clinical laboratory measures.
Request a sample and discover the recent advances in Spinal Cord Injury Treatment Drugs @ Spinal Cord Injury Pipeline Report
In the Spinal Cord Injury pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Spinal Cord Injury clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Spinal Cord Injury collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Spinal Cord Injury Overview
Spinal Cord Injury (SCI) is a condition in which damage to any part of the spinal cord or nerves at the end of the spinal canal (cauda equina) occurs. Spinal Cord Injury can be traumatic or non-traumatic. The symptoms of SCI will depend on the type (complete or incomplete) and location of the damage and includes weakness in the arms and/or legs, difficulty breathing, severe pain or pressure in the neck or back, decreased sensation in the arms and/or legs, unusual lumps along the spine, and loss of bladder or bowel control.
Find out more about Spinal Cord Injury Therapeutics Assessment @ Spinal Cord Injury Preclinical and Discovery Stage Products
Spinal Cord Injury Emerging Drugs Profile
- ES 135: Eusol Biotech
- MT-3921: Mitsubishi Tanabe Pharma Corporation
Spinal Cord Injury Pipeline Therapeutics Assessment
There are approx. 35+ key companies which are developing the Spinal Cord Injury therapies. The Spinal Cord Injury companies which have their Spinal Cord Injury drug candidates in the most advanced stage, i.e. Phase III include, Eusol Biotech.
DelveInsight’s Spinal Cord Injury Pipeline Report covers around 35+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Spinal Cord Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Spinal Cord Injury Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Learn more about the emerging Spinal Cord Injury Pipeline Therapies @ Spinal Cord Injury Clinical Trials Assessment
Scope of the Spinal Cord Injury Pipeline Report
- Coverage- Global
- Spinal Cord Injury Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Spinal Cord Injury Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Spinal Cord Injury Companies- Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.
- Spinal Cord Injury Pipeline Therapies- KAI-1678, Tadalafil, NVG-291, GRNOPC1, MT-3921, ALMB-0166, NeuroAiD, and others.
Dive deep into rich insights for new drugs for Spinal Cord Injury Treatment, Visit @ Spinal Cord Injury Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Spinal Cord Injury: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Spinal Cord Injury – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- ES 135: Eusol Biotech
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- MT-3921: Mitsubishi Tanabe Pharma Corporation
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- NVG 291: NervGen Pharma
- Drug profiles in the detailed report…..
- Preclinical/Discovery Stage Products
- KAND-567: Kancera
- Drug profiles in the detailed report…..
- Inactive Products
- Spinal Cord Injury Key Companies
- Spinal Cord Injury Key Products
- Spinal Cord Injury- Unmet Needs
- Spinal Cord Injury- Market Drivers and Barriers
- Spinal Cord Injury- Future Perspectives and Conclusion
- Spinal Cord Injury Analyst Views
- Appendix
For further information on the Spinal Cord Injury Pipeline therapeutics, reach out to Spinal Cord Injury Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/spinal-cord-injury-market
){kind=link}